CL King Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $116
Portfolio Pulse from Benzinga Newsdesk
CL King has initiated coverage on Haemonetics with a Buy rating and set a price target of $116, indicating a positive outlook for the company's stock.
September 13, 2024 | 7:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CL King has initiated coverage on Haemonetics with a Buy rating and a price target of $116, suggesting a positive short-term outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $116 by CL King is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100